Rosmarinic Acid Intravitreal Implants: A New Therapeutic Approach for Ocular Neovascularization release_yjwyjna4gzehbhdwqc32vd6lem

by Lorena Carla Vieira, Carolina Paula de Souza Moreira, Brenda Fernanda Moreira Castro, Oliver Araújo Lacerda Cotta, Luciana Maria Silva, Gustavo de Oliveira Fulgêncio, Armando Silva-Cunha, Sílvia L. Fialho

Published in Planta Medica by Georg Thieme Verlag KG .



<jats:title>Abstract</jats:title>Rosmarinic acid, a plant-derived compound with antiangiogenic activity, can be applied for the treatment of ocular diseases related to neovascularization, such as diabetic retinopathy, macular edema, and age-related macular degeneration. These diseases represent the leading causes of blindness worldwide if they are not properly treated. Intravitreal devices allow for localized drug delivery to the posterior segment, increasing the drug bioavailability and promoting extended release, thus, reducing side effects and enhancing the patient's compliance to the treatment. In this work, rosmarinic acid-loaded poly lactic-co-glycolic acid intraocular implants were developed with a view for the treatment of ocular neovascularization. Physical-chemical, biocompatibility, and safety studies of the implants were carried out in vitro and in vivo as well as an evaluation of the antiangiogenic activity in a chorioallantoic membrane assay. Data obtained showed that rosmarinic acid released from the implants was quantified in the vitreous for 6 weeks, while when it was in the solution formulation, after 24 h, no drug was found in the vitreous. The delivery device did not show any sign of toxicity after clinical evaluation and in electroretinographic findings. Histological analysis showed normal eye tissue. Rosmarinic acid released from implants reduced 30% of new vessel's formation. The intravitreal implant successfully allowed for the prolonged release of rosmarinic acid, was safe to rabbits eyes, and demonstrated activity in vessel reduction, thus demonstrating potential in preventing neovascularization in ophthalmic diseases.
In application/xml+jats format

Archived Files and Locations

application/pdf  605.4 kB
file_rfk6idinindpram6o6qzgqbyiy (webarchive) (web)
Read Archived PDF
Type  article-journal
Stage   published
Date   2020-08-14
Language   en ?
DOI  10.1055/a-1223-2525
PubMed  32797466
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  0032-0943
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 5add2e80-60cc-4a0b-8ac3-bf01f5ad70f7